Article Text

Download PDFPDF

S115 Hot-hmv uk trial secondary outcome analysis: early readmission is reduced by the addition of home mechanical ventilation to home oxygen therapy in copd patients with chronic respiratory failure following a life-threatening exacerbation
  1. PB Murphy1,
  2. G Arbane1,
  3. S Bourke2,
  4. P Calverley3,
  5. A Crooks4,
  6. L Dowson5,
  7. N Duffy6,
  8. GJ Gibson7,
  9. P Hughes8,
  10. JR Hurst9,
  11. K Lewis10,
  12. R Mukherjee11,
  13. A Nickol12,
  14. N Oscroft13,
  15. J Pepperell14,
  16. S Rehal4,
  17. I Smith13,
  18. J Stradling12,
  19. W Wedizcha15,
  20. MI Polkey15,
  21. M Elliott16,
  22. N Hart1
  1. 1Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  2. 2Northumbria Healthcare NHS Foundation Trust, Newcastle, UK
  3. 3University of Liverpool, Liverpool, UK
  4. 4MRC Clinical Trials Unit, UCL, London, UK
  5. 5Royal Wolverhampton NHS Trust, Wolverhampton, UK
  6. 6Aintree University Hospital, Liverpool, UK
  7. 7Newcastle University, Newcastle, UK
  8. 8Plymouth Hospital NHS Trust, Plymouth, UK
  9. 9Royal Free Hospital, London, UK
  10. 10Swansea University, Swansea, UK
  11. 11Heart of England NHS Trust, Birmngham, UK
  12. 12Oxford University, Oxford, UK
  13. 13Papworth Hospital, Cambridge, UK
  14. 14Taunton and Somerset NHS Trust, Taunton, UK
  15. 15Royal Brompton and Harefield NHS Foundation Trust, London, UK
  16. 16Leeds University Hospital, Leeds, UK


Introduction Hospital readmission following treatment for a life-threatening exacerbation of COPD with acute NIV is frequent and associated with an adverse impact in terms of lung function and health related quality of life. They have been identified as a priority area in the NHS with financial penalties for any patient readmitted within 28 days following discharge.

Method A multicentre open labelled randomised controlled trial recruited patients with persistent hypercapnia (PaCO2 > 7 kPa) 2–4 weeks following resolution of acute acidosis. Patients were randomised to either home oxygen therapy (HOT) or HOT and home mechanical ventilation (HOT-HMV). HMV was titrated overnight to control nocturnal hypercapnia. Follow up was for 12 months. The primary outcome, 12-month admission free survival, has been reported previously demonstrating a significant treatment effect (ERS 2016). Secondary outcome analysis included 28-day all-cause hospital readmission and 12 month exacerbation rate.

Results 116 patients were randomised (HOT = 59, HOT-HMV = 57), age 67 ± 10 years, FEV1 0.6 ± 0.2 L, PaCO2 7.9 ± 0.9 kPa. 28-day readmission was 22 (37%) in the HOT and 7 (12%) in the HOT-HMV arm (unadjusted HR 0.27, 0.12 to 0.63, p = 0.003; adjusted HR 0.26, 0.11 to 0.61, p = 0.002) (Figure 1). 12 month exacerbation rate was reduced from median 5 (1 to 9) per year in the HOT arm to 4 (2to 6) in the HOT-HMV arm (unadjusted HR 0.64 (0.44 to 0.94); p = 0.022; adjusted HR 0.66, 0.46 to 0.95, p = 0.026).

Conclusion The addition of HMV to HOT in patients with persistent hypercapnia following an acute life-threatening exacerbation of COPD reduces both 28-day readmission and 12 month exacerbation frequency. These data strongly support a change in clinical practice in the management of patients with severe COPD and persistent hypercapnia.

Abstract S115 Figure 1

Time to hospital re-admission by treatment arm

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.